The AAPS Journal

, Volume 7, Issue 4, pp E834–E846

Mechanisms of drug-induced delayed-type hypersensitivity reactions in the skin

Authors

  • Sanjoy Roychowdhury
    • Division of Pharmaceutics, College of PharmacyThe University of Iowa
    • Division of Pharmaceutics, College of PharmacyThe University of Iowa
Article

DOI: 10.1208/aapsj070480

Cite this article as:
Roychowdhury, S. & Svensson, C.K. AAPS J (2005) 7: E834. doi:10.1208/aapsj070480

Abstract

Cutaneous drug reactions (CDRs) are the most commonly reported adverse drug reactions. These reactions can range from mildly discomforting to life threatening. CDRs can arise either from immunological or nonimmunological mechanisms, though the preponderance of evidence suggests an important role for immunological responses. Some cutaneous eruptions appear shortly after drug intake, while others are not manifested until 7 to 10 days after initiation of therapy and are consistent with delayed-type hypersensitivity. This review discusses critical steps in the initiation of delayed-type hypersensitivity reactions in the skin, which include protein haptenation, dendritic cell activation/migration and T-cell propagation. Recently, an alternative mechanism of drug presentation has been postulated that does not require bioactivation of the parent drug or antigen processing to elicit a drug-specific T-cell response. This review also discusses the role of various immune-mediators, such as cytokines, nitric oxide, and reactive oxygen species, in the development of delayed-type drug hypersensitivity reactions in skin. As keratinocytes have been shown to play a crucial role in the initiation and propagation of cutaneous immune responses, we also discuss the means by which these cells may initiate or modulate CDRs.

Keywords

cutaneous drug reactionsdelayed-type hypersensitivitydendritic cellskeratinocytesT-cellscytokines

Copyright information

© American Association of Pharmaceutical Scientists 2005